Use of Thiazolidinediones and Fracture Risk

Christian Meier, MD; Marius E. Kraenzlin, MD; Michael Bodmer, MD; Susan S. Jick, DSc; Hershel Jick, MD; Christoph R. Meier, PhD

Background: Thiazolidinediones may adversely affect the skeleton owing to decreased bone formation and accelerated bone loss.

Methods: This study examines the association between the use of thiazolidinediones or other oral antidiabetic drugs and the risk of fracture. This nested case-control analysis uses the UK General Practice Research Database, including case patients with fracture aged 30 to 89 years with an incident fracture diagnosis between January 1994 and December 2005 and control subjects who were matched to case patients on age, sex, calendar time, and general practice attended. We assessed the odds ratios (ORs) of having a fracture associated with the use of rosiglitazone maleate, pioglitazone hydrochloride, other oral antidiabetic agents, or insulin.

Results: There were 1020 case patients with an incident low-trauma fracture and 3728 matched controls. After adjustment for age, body mass index, other antidiabetic drugs, comedication, and comorbidities, the ORs for users of 8 or more thiazolidinedione prescriptions (corresponding to approximately 12-18 months of therapy) compared with nonuse was 2.43 (95% confidence interval [CI], 1.49-3.95). Rosiglitazone (OR, 2.38; 95% CI, 1.39-4.09) and pioglitazone (OR, 2.59; 95% CI, 0.96-7.01) were used more frequently by case patients with fracture (predominantly hip and wrist fractures) than by controls. The association was independent of patient age and sex and tended to increase with thiazolidinedione dose. No materially altered relative fracture risk was found in association with the use of other oral antidiabetic drugs.

Conclusion: This analysis provides further evidence of a possible association between long-term use of thiazolidinediones and fractures, particularly of the hip and wrist, in patients with diabetes mellitus.

Arch Intern Med. 2008;168(8):820-825

OSTEOPOROTIC FRACTURES are associated with significant morbidity and mortality and a reduction in quality of life. An estimated 30% to 50% of women and 15% to 30% of men will experience a fracture related to osteoporosis in their lifetime. Patients with type 2 diabetes mellitus (DM) have been shown to have higher bone density1-4 and, thus, might be expected to be at lower risk for fracture.5 In contrast, however, studies in community-dwelling individuals have shown an increased risk of fragility fractures, predominantly at nonvertebral sites,6-11 independent of age, body mass index (BMI), and bone density.12 The increased risk might, therefore, be related to other factors, such as diabetic complications, risk of falls, and, potentially, antidiabetic medication use.

The insulin-sensitizing thiazolidinediones are a relatively new and effective class of oral antidiabetic agents that have gained wide use in clinical conditions characterized by insulin resistance. Pioglitazone hydrochloride and rosiglitazone maleate account for 21% of the oral antidiabetic drugs in the United States and 5% in Europe.13 Preclinical14-18 and clinical19-21 studies indicate that thiazolidinediones may exert unfavorable effects on bone, resulting in reduced osteoblastic bone formation and accelerated bone loss. In a recent, large, randomized, clinical trial22 comparing the glycemic control of rosiglitazone relative with metformin hydrochloride or glyburide monotherapies, an increased risk of distal upper and distal lower limb fractures in women with type 2 DM treated with rosiglitazone was observed. Based on a Food and Drug Administration MedWatch safety information alert, an increased fracture risk seems to be related to the use of pioglitazone too, indicating a possible class effect of thiazolidinediones.23,24

Given that the use of rosiglitazone and pioglitazone is becoming more common, it is important to determine whether these drugs impair skeletal health and increase fracture risk. Specifically, it remains unclear whether thiazolidinedione use is as-
Data were derived from the UK-based General Practice Research Database (GPRD), which has been described previously. Briefly, this database was established around 1987 and currently encompasses approximately 5 million people who are enrolled with selected general practitioners, covering more than 50 million patient-years of follow-up. The patients enrolled in the GPRD are representative of the United Kingdom regarding age, sex, geographic distribution, and annual turnover rate. General practitioners have been trained to record medical information, including demographic data, medical diagnoses, hospitalizations, deaths, and drug prescriptions, using standard software and standard coding systems. The general practitioners generate prescriptions directly using the computer, and this information is automatically transcribed into the computer record. It contains the name of the preparation, route of administration, dose, and number of tablets for each prescription. The recorded information on drug exposure and diagnoses has been validated and proved to be of high quality.

METHODS

DATA SOURCE

We assessed, from the computer records, exposure to oral antidiabetic agents and insulin before the index date in case patients with fracture and controls. We classified users of oral antidiabetic drugs according to drug class (thiazolidinediones, sulfonylureas, metformin, prandial glucose regulators, or α-glucosidase inhibitors), timing of exposure (“current use” if the last prescription for a drug of interest was recorded <60 days or “past use” if it was recorded ≥60 days before the index date), and duration of use, based on the number of prescriptions before the index date; we classified duration of thiazolidinedione use into categories of 1 to 7, 8 to 14, or ≥15 or more prescriptions. For insulin, prandial glucose regulators, and acarbose, categories were defined as use of 1 to 9, 10 to 19, 20 to 29, or ≥30 or more prescriptions; and for sulfonylureas and metformin (owing to a higher exposure prevalence of these drugs), groups were divided into use of 1 to 9, 10 to 19, 20 to 29, 30 to 39, or ≥40 or more prescriptions.

We conducted conditional logistic regression analyses using a software program (SAS 8.1; SAS Institute Inc, Cary, North Carolina). Risk estimates are presented as odds ratios (ORs) with 95% confidence intervals (CIs). The P values are 2-sided, and P<.05 was considered statistically significant. We compared thiazolidinedione use with nonuse of thiazolidinediones and adjusted for use of other antidiabetic agents and for smoking status (none, current, past, or unknown); BMI (calculated as weight in kilograms divided by height in meters squared) (<25, 25-29.9, and ≥30); a variety of diagnosed comorbidities potentially associated with an altered fracture risk, such as chronic renal failure, diabetic neuropathy, diabetic retinopathy, asthma/chronic obstructive pulmonary disease, congestive heart failure, a history of stroke/transient ischemic attack, epilepsy, or rheumatoid arthritis; and use of antihypertensive drugs, diuretics, lipid-lowering agents, inhaled or systemic corticosteroids, antiepileptic drugs, benzodiazepines, antipsychotic agents, or antidepressants in the multivariate model. We further assessed the duration of DM history, defined as the period between the first DM diagnosis or the first prescription for an oral antidiabetic drug and the index date.

RESULTS

The study population consisted of 66 696 diabetic patients: 16 648 had a DM diagnosis with no treatment with oral antidiabetic agents or insulin, and 50 048 received at least 1 prescription for at least 1 study drug. The mean (SD) age of the study population was 60.7 (11.7) years, and 54.8% were women. In the study population, we identified 1020 case patients with fracture and 3728 matched controls. Clinically diagnosed low-trauma fractures consisted of 301 wrist/forearm, 274 hip, 222 humerus, 148 rib, 56 vertebral, and 19 other, unspecified fractures.
The age and sex distribution and the prevalence of relevant comorbidities of case patients and controls, together with crude and adjusted independent ORs, are given in Table 1. Of the 1020 case patients with fracture and their 3728 controls, 208 and 762, respectively, did not use any oral antidiabetic drugs or insulin. Of the remaining 812 case patients who used antidiabetic drugs, 65 used thiazolidinediones, all in combination with other oral antidiabetic agents, smoking, BMI, comorbidities, and nonuse of thiazolidinediones and adjusted for the use of other antidiabetic drugs, and 747 used other oral antidiabetic agents.

Preclinical14,16-18 and clinical10-21 studies indicate that thiazolidinedione (glitazone) use may have adverse effects on bone metabolism, resulting in reduced osteoblastic function compared with nonuse was 2.43 (95% CI, 1.49-3.95). We then stratified the group of current users of 8 or more thiazolidinedione prescriptions by sex and age, yielding adjusted ORs of 2.50 (95% CI, 0.84-7.41) for men, 2.56 (95% CI, 1.43-4.58) for women, 2.96 (95% CI, 1.40-6.25) for patients younger than 70 years, and 2.57 (95% CI, 1.22-5.40) for those 70 years and older. We also stratified thiazolidinedione users by individual thiazolidinedione and by tablet dose. Current use of 8 or more prescriptions for pioglitazone or rosiglitazone yielded adjusted ORs of 2.59 (95% CI, 0.96-7.01) and 2.38 (95% CI, 1.39-4.09), respectively. The adjusted risk estimates for current use of 8 or more prescriptions of a low dose (4 mg of rosiglitazone maleate or 15 mg of pioglitazone hydrochloride) or of a high dose (8 mg of rosiglitazone maleate or 30 mg of pioglitazone hydrochloride) were 2.14 (95% CI, 1.15-3.92) and 2.98 (95% CI, 1.42-6.26), respectively. Adjusted risk estimates stratified by fracture site are given in Table 3.

Table 1. Characteristics and Comorbidities of Fracture Case Patients and Control Subjects With Diabetes Mellitus

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Case Patients (n=1020)</th>
<th>Control Subjects (n=3728)</th>
<th>Crude</th>
<th>Adjusteda</th>
<th>OR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>63 (6.2)</td>
<td>186 (5.0)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>50-59</td>
<td>115 (11.3)</td>
<td>408 (10.9)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>60-69</td>
<td>242 (23.7)</td>
<td>957 (25.7)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>70-79</td>
<td>438 (42.9)</td>
<td>1642 (44.0)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>≥ 80</td>
<td>162 (15.9)</td>
<td>535 (14.4)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>318 (31.2)</td>
<td>1187 (31.8)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Female</td>
<td>702 (68.8)</td>
<td>2541 (68.2)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>515 (50.5)</td>
<td>1971 (52.9)</td>
<td>1 [Reference]</td>
<td>1 [Reference]</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Current</td>
<td>158 (15.5)</td>
<td>521 (14.0)</td>
<td>1.18 (0.96-1.46)</td>
<td>1.08 (0.87-1.35)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Past</td>
<td>273 (26.8)</td>
<td>952 (25.5)</td>
<td>1.14 (0.96-1.36)</td>
<td>1.06 (0.88-1.28)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Unknown</td>
<td>74 (7.2)</td>
<td>284 (7.6)</td>
<td>0.94 (0.69-1.29)</td>
<td>1.01 (0.70-1.46)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>BMI b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 25.0</td>
<td>213 (20.9)</td>
<td>647 (17.4)</td>
<td>1 [Reference]</td>
<td>1 [Reference]</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>25.0-29.9</td>
<td>355 (34.8)</td>
<td>1214 (32.6)</td>
<td>0.90 (0.74-1.10)</td>
<td>0.92 (0.75-1.14)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>≥ 30.0</td>
<td>349 (34.2)</td>
<td>1483 (39.8)</td>
<td>0.69 (0.56-0.85)</td>
<td>0.65 (0.52-0.82)</td>
<td>&lt;.001</td>
<td>NA</td>
</tr>
<tr>
<td>Unknown</td>
<td>103 (10.1)</td>
<td>384 (10.3)</td>
<td>0.80 (0.60-1.06)</td>
<td>0.83 (0.60-1.15)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>61 (6.0)</td>
<td>179 (4.8)</td>
<td>1.32 (0.98-1.78)</td>
<td>1.26 (0.91-1.74)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Diabetic retinopathy</td>
<td>14 (1.4)</td>
<td>46 (1.2)</td>
<td>1.13 (0.61-2.10)</td>
<td>1.24 (0.65-2.35)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Diabetic neuropathy</td>
<td>13 (1.3)</td>
<td>63 (1.7)</td>
<td>0.77 (0.41-1.45)</td>
<td>0.72 (0.37-1.42)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Asthma/CPUD</td>
<td>222 (21.8)</td>
<td>640 (17.2)</td>
<td>1.34 (1.13-1.60)</td>
<td>1.22 (0.97-1.54)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>136 (13.3)</td>
<td>423 (11.3)</td>
<td>1.23 (0.97-1.49)</td>
<td>1.17 (0.92-1.49)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Stroke/TIA</td>
<td>156 (15.3)</td>
<td>424 (11.4)</td>
<td>1.41 (1.15-1.73)</td>
<td>1.35 (1.09-1.66)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>47 (4.6)</td>
<td>114 (3.1)</td>
<td>1.52 (1.07-2.16)</td>
<td>1.53 (1.08-2.22)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>31 (3.0)</td>
<td>59 (1.6)</td>
<td>1.85 (1.18-2.89)</td>
<td>1.40 (0.82-2.39)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CI, confidence interval; COPD, chronic obstructive pulmonary disease; NA, not applicable; TIA, transient ischemic attack.

a Adjusted for all the variables displayed, including use of oral antidiabetic agents, insulin, antihypertensive drugs, lipid-lowering agents, diuretics, inhaled and systemic corticosteroids, anticonvulsants, antidepressants, neuroleptics, benzodiazepines, and analgesics.

b Percentages may not total 100 because of rounding.

To gain statistical power and because the risk estimates were similar for users of 8 to 14 and 15 or more prescriptions, we combined current users of 8 to 14 or of 15 or more prescriptions into 1 group for further analyses; the adjusted OR for current use of 8 or more thiazolidinedione prescriptions compared with nonuse was 2.43 (95% CI, 1.49-3.95). We then stratified the group of current users of 8 or more thiazolidinedione prescriptions by sex and age, yielding adjusted ORs of 2.50 (95% CI, 0.84-7.41) for men, 2.56 (95% CI, 1.43-4.58) for women, 2.96 (95% CI, 1.40-6.25) for patients younger than 70 years, and 2.57 (95% CI, 1.22-5.40) for those 70 years and older. We also stratified thiazolidinedione users by individual thiazolidinedione and by tablet dose. Current use of 8 or more prescriptions for pioglitazone or rosiglitazone yielded adjusted ORs of 2.59 (95% CI, 0.96-7.01) and 2.38 (95% CI, 1.39-4.09), respectively. The adjusted risk estimates for current use of 8 or more prescriptions of a low dose (4 mg of rosiglitazone maleate or 15 mg of pioglitazone hydrochloride) or of a high dose (8 mg of rosiglitazone maleate or 30 mg of pioglitazone hydrochloride) were 2.13 (95% CI, 1.15-3.92) and 2.98 (95% CI, 1.42-6.26), respectively. Adjusted risk estimates stratified by fracture site are given in Table 3.

COMMENT

Preclinical14,16-18 and clinical10-21 studies indicate that thiazolidinedione (glitazone) use may have adverse effects on bone metabolism, resulting in reduced osteoblastic...
bone formation and accelerated bone loss. The findings of this large, population-based, nested, case-control analysis provide further evidence that current use of rosiglitazone and pioglitazone in women and men with type 2 DM may be associated with an approximately 2- to 3-fold increased risk of hip and nonvertebral osteoporotic fractures. The numbers of vertebral and rib fractures were too low for a meaningful assessment of fracture risk in relation to thiazolidinedione use. Although short-term exposure to thiazolidinediones did not materially alter the relative risk estimate of developing a fracture, the OR was increased for current users of 8 or more prescriptions, corresponding to approximately 12 to 18 months of therapy. Fracture risk was independent of BMI, comorbidities, diabetic complications, DM duration, and use of other oral antidiabetic drugs.

Treatment with thiazolidinediones has recently been reported to possibly increase the risk of fractures in a randomized trial exploring the efficacy of rosiglitazone, metformin, or glyburide encompassing 4360 patients with type 2 DM. The authors of A Diabetes Outcome Progression Trial (ADOPT) reported an unexpected observation that was not part of the prespecified analysis plan: more women taking rosiglitazone experienced fractures of the upper or lower limbs compared with women taking the comparison antidiabetic drugs. Furthermore, findings from clinical trial databases underline an excess of fractures in patients treated with pioglitazone, suggesting that the increased fracture risk may be a class effect of thiazolidinediones. For pioglitazone, the incidence was 1.9 fractures per 100 patient-years in the pioglitazone-treated group compared with 1.1 fractures in the comparator-treated group, which translates to an excess risk of 0.8 fractures per 100 patient-years of use for women taking the drug. The present findings support this recent observation and indicate a possible class effect of thiazolidinediones because current use of 8 or more prescriptions of rosiglitazone (OR, 2.38; 95% CI, 1.39-4.09) or pioglitazone (OR, 2.59; 95% CI, 0.96-7.01) was associated with increased nonvertebral fracture risk. Recently published data indicate that thiazolidinedione-associated fractures are restricted to the lower limb (foot, ankle, fibula, and tibia) and upper limb (forearm, hand, and wrist) despite the fact that in healthy postmenopausal women and older diabetic patients bone loss during thiazolidinedione use was observed at sites related to osteoporotic fractures (ie, the lumbar spine and the femoral neck). This study was particularly designed...
to investigate the association between the use of thiazolidinediones and fractures classically related to osteoporosis. In contrast to the findings by Kahn et al., we found that thiazolidinedione use may also affect fractures at the femoral neck. Apart from methodological issues, the age of the study population might explain differences in the types of fractures observed: the average age of participants in ADOPT was in the middle 50s, whereas in the present cohort approximately 60% were older than 60 years at the index date. Because the incidence of fractures at the spine and hip increases with age, previous findings in younger individuals with fractures at the lower and upper distal limbs might reflect the kinds of fractures that younger women would tend to experience.

Furthermore, it may be speculated that thiazolidinediones might have differential effects on bone with respect to patient age. Rosiglitazone-induced bone loss in adult and old animals seems to occur via distinct cellular mechanisms. Although bone loss in adult mice was associated with a decreased number of osteoblasts and a decreased bone formation rate, bone loss in older animals was a direct result of increased osteoclast numbers. If confirmed in further studies, these findings could turn out to be particularly relevant because increasing numbers of young patients are being considered for treatment with thiazolidinediones. To our knowledge, no data are available on the effect of thiazolidinediones on the acquisition of peak bone mass in overweight and insulin-resistant teenagers receiving thiazolidinediones.

Thiazolidinediones are ligands for peroxisome proliferator-activated receptor γ (PPARγ), a family of nuclear receptors that regulate gene transcription; PPARγs are most abundant in adipocytes and regulate their differentiation and function. When added to bone marrow cultures, it has been demonstrated that rosiglitazone stimulates adipogenesis and inhibits osteoblastogenesis. Hence, a shift in the flow of mesenchymal precursor cells from osteoblastic to adipogenic lineages mediated by activation of PPARγ may result in reduced bone formation and, ultimately, bone loss. Consistently, recent studies in rodent models and humans indicate that exposure to thiazolidinediones impairs osteoblastic function, resulting in reduced bone formation and bone mass. In contrast, results of studies evaluating the short-term effects of rosiglitazone on osteoblastic bone resorption demonstrated that thiazolidinediones do not affect bone resorption in vivo. Nevertheless, uncoupling of bone formation from bone resorption was accompanied by early bone loss. These changes resemble the pattern of alteration of bone remodeling after initiation of glucocorticoid therapy, which is accompanied by rapid bone loss and increased risk of fragility fractures. In this study, short-term exposure did not materially alter the fracture risk, whereas fracture risk increased in current users with therapy duration of 12 months and more.

Results of clinical trial databases and findings from ADOPT indicated that the increased risk of fractures is limited to women. In contrast, the present findings do not necessarily support the proposition that a deleterious effect on bones may be restricted to women because in this study the fracture risk was also increased in men.

Accelerated bone loss has been observed in postmenopausal women and older men treated with thiazolidinediones. Ultimately, randomized controlled trials that include women and men are needed to provide evidence for or against a sex difference in the skeletal response to glitazones.

This study has several limitations. First, we cannot exclude the possibility that some fractures may have been missed or misclassified. We focused on clinical osteoporotic fractures resulting from low trauma. Systematic radiographic screening to identify asymptomatic vertebral deformities and fractures is not available; consequently, the number of vertebral fractures may be underestimated. Second, it is conceivable that certain demographic or lifestyle factors, such as socioeconomic status, dietary habits, and physical activity, are associated with fracture risk and with use of antidiabetic drugs. However, a distortion could have occurred only if a confounder were a strong risk factor for fractures and at the same time associated particularly with the use of thiazolidinediones but not with other antidiabetic agents. To control for socioeconomic status, as much as possible, case patients and controls were matched on general practice. Third, although we adjusted for asthma/chronic obstructive pulmonary disease (and thereby, to some degree, for corticosteroid use) and for a history of stroke, it is conceivable that the observed fracture risk could have been the result of residual confounding by these risk factors. We, therefore, conducted a sensitivity analysis in which we excluded individuals with asthma/chronic obstructive pulmonary disease or stroke; the OR for current thiazolidinedione use of 15 or more prescriptions even increased (adjusted OR, 5.62; 95% CI, 2.33-13.60). Fourth, it is conceivable that patients treated with oral antidiabetic drugs were selected for therapy because of a history of fracture or other bone loss.

Table 3. Current Use of TZDs and Fracture Risk by Fracture Site

<table>
<thead>
<tr>
<th>Fracture Site</th>
<th>Participants, No. (%)a</th>
<th>Current TZD use</th>
<th>No TZD use</th>
<th>Adjusted OR (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case Patients</td>
<td>Control Subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip/femur</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No TZD use</td>
<td>261 (95.3)</td>
<td>977 (96.3)</td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>Current TZD use</td>
<td>3 (1.1)</td>
<td>9 (0.9)</td>
<td>1.40 (0.31-6.30)</td>
<td></td>
</tr>
<tr>
<td>≥ 8 Rx</td>
<td>8 (2.9)</td>
<td>12 (1.2)</td>
<td>4.54 (1.28-16.10)</td>
<td></td>
</tr>
<tr>
<td>Humerus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No TZD use</td>
<td>207 (93.2)</td>
<td>757 (94.4)</td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>Current TZD use</td>
<td>2 (0.9)</td>
<td>12 (1.5)</td>
<td>0.28 (0.04-1.92)</td>
<td></td>
</tr>
<tr>
<td>≥ 8 Rx</td>
<td>7 (3.2)</td>
<td>18 (2.2)</td>
<td>2.12 (0.62-7.26)</td>
<td></td>
</tr>
<tr>
<td>Wrist/forearm</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No TZD use</td>
<td>277 (92.0)</td>
<td>1028 (93.0)</td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>Current TZD use</td>
<td>5 (1.7)</td>
<td>25 (2.3)</td>
<td>0.74 (0.23-2.35)</td>
<td></td>
</tr>
<tr>
<td>≥ 8 Rx</td>
<td>14 (4.7)</td>
<td>22 (2.0)</td>
<td>2.90 (1.19-7.10)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio; Rx, prescription; TZDs, thiazolidinediones.

a Percentages do not total 100 because data for the “past user” category are not displayed.

b Adjusted for all the variables displayed in Table 1 plus the use of sulfonylureas, metformin, prandial glucose inhibitors, acarbose, insulin, antihypertensives, lipid-lowering agents, diuretics, inhaled and systemic corticosteroids, anticonvulsants, antidepressants, neuroleptics, benzodiazepines, and analgesics.
betic agents contributed different amounts of person-time than untreated patients with DM, which could lead to a distortion of the fracture risk. We, therefore, adjusted for duration of DM history, which left the results unchanged. Finally, the present finding of an increased fracture risk associated with thiazolidinedione use may be real, but it does not prove an adverse effect of thiazolidinedione on bone mass. In theory, alternative explanations for the observed association are conceivable.

In summary, this nested case-control analysis of diabetic patients provides additional evidence that the use of thiazolidinediones for approximately 12 or more months may increase the risk of osteoporotic nonvertebral fractures. No such effect was seen for other antidiabetic drugs in this study population. These findings, although they are consistent with recently reported data from a randomized trial,22 are based on relatively few thiazolidinedione-exposed patients and need to be confirmed by additional observational studies and by controlled clinical trials.

Accepted for Publication: August 19, 2007.
Correspondence: Christoph R. Meier, PhD, Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, CH-4031 Basel, Switzerland (meierch@uhbs.ch).

Financial Disclosure: None reported.

REFERENCES